Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
1.93B
Market cap1.93B
Price-Earnings ratio
-6.16
Price-Earnings ratio-6.16
Dividend yield
Dividend yield
Average volume
8.13M
Average volume8.13M
High today
$18.43
High today$18.43
Low today
$17.20
Low today$17.20
Open price
$17.51
Open price$17.51
Volume
408.71K
Volume408.71K
52 Week high
$138.81
52 Week high$138.81
52 Week low
$10.42
52 Week low$10.42

Stock Snapshot

Sarepta Therapeutics(SRPT) stock is priced at $18.39, giving the company a market capitalization of 1.93B. It carries a P/E multiple of -6.16.

On 2025-11-14, Sarepta Therapeutics(SRPT) stock traded between a low of $17.20 and a high of $18.43. Shares are currently priced at $18.39, which is +6.9% above the low and -0.2% below the high.

Sarepta Therapeutics(SRPT) shares are trading with a volume of 408.71K, against a daily average of 8.13M.

In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.

In the last year, Sarepta Therapeutics(SRPT) shares hit a 52-week high of $138.81 and a 52-week low of $10.42.

SRPT News

Simply Wall St 23h
A Look at Sarepta Therapeutics Valuation Following Mixed ESSENCE Trial Results and Earnings Shift

Sarepta Therapeutics (SRPT) shares drew attention after the company announced mixed outcomes from its pivotal ESSENCE Phase 3 trial. Although the main goal did...

A Look at Sarepta Therapeutics Valuation Following Mixed ESSENCE Trial Results and Earnings Shift
Simply Wall St 4d
Should Investors View Sarepta Differently After ESSENCE Study Details and Q3 Results?

In the past week, Sarepta Therapeutics reported third-quarter 2025 earnings with revenue of US$399.36 million and a net loss of US$179.95 million, alongside ann...

Should Investors View Sarepta Differently After ESSENCE Study Details and Q3 Results?

Analyst ratings

54%

of 26 ratings
Buy
26.9%
Hold
53.8%
Sell
19.2%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.